And Then There Was One: NewLink Genetics Refocuses Efforts On Indoximod, Its Remaining, Undervalued Late-Stage Asset
Seeking Alpha,
Summary NewLink has evolved into a primarily single asset company and refocused itself to advance its late stage immune-oncology…